Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Total Non-Current Liabilities (2020 - 2025)

Lyell Immunopharma's Total Non-Current Liabilities history spans 6 years, with the latest figure at $76.2 million for Q3 2025.

  • For Q3 2025, Total Non-Current Liabilities fell 10.35% year-over-year to $76.2 million; the TTM value through Sep 2025 reached $76.2 million, down 10.35%, while the annual FY2024 figure was $104.8 million, 14.62% up from the prior year.
  • Total Non-Current Liabilities for Q3 2025 was $76.2 million at Lyell Immunopharma, down from $83.5 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $207.0 million in Q2 2021 and bottomed at $76.2 million in Q3 2025.
  • The 5-year median for Total Non-Current Liabilities is $94.1 million (2023), against an average of $121.1 million.
  • The largest annual shift saw Total Non-Current Liabilities plummeted 50.31% in 2023 before it rose 14.62% in 2024.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $193.1 million in 2021, then plummeted by 48.1% to $100.2 million in 2022, then fell by 8.77% to $91.4 million in 2023, then increased by 14.62% to $104.8 million in 2024, then fell by 27.31% to $76.2 million in 2025.
  • Per Business Quant, the three most recent readings for LYEL's Total Non-Current Liabilities are $76.2 million (Q3 2025), $83.5 million (Q2 2025), and $90.1 million (Q1 2025).